Skip to main content
Fig. 13 | Journal of Experimental & Clinical Cancer Research

Fig. 13

From: Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma

Fig. 13

Effects of MDM2 expression on RCC patient survival probability: Kaplan-Meier survival analyses of OS from TCGA-RCC cohorts of ccRCC (A), chRCC (B) and pRCC (C) were presented. Patients were grouped into the high MDM2 expression group versus the low MDM2 expression group based on the median MDM2 mRNA expression. Each p-value for its significance from high versus low MDM2 expression was calculated using the log-rank test. The figures were performed using R version 4.0.3

Back to article page